News Releases

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

201120102009200820072003

Aug 8, 2018

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2018. Cash and investments in marketable securities at June 30, 2018 were $2.1 billion...

More
Aug 1, 2018

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Wednesday, August 8, 2018, after the close of U.S.-based financial markets. Howard Robin, president...

More
Jul 30, 2018
NKTR-181 is a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy

Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review the company's New Drug Application (NDA) for NKTR-181 for the...

More
Jun 14, 2018

Nektar Therapeutics (Nasdaq: NKTR) today announced that new clinical and preclinical data for NKTR-181 were presented this week at the 80th Annual Scientific Meeting of the College on Problems of...

More
Jun 5, 2018

Nektar Therapeutics' (Nasdaq: NKTR) Senior Vice President and Chief Scientific Officer, Jonathan Zalevsky, Ph.D., is scheduled to present at the upcoming Jefferies 2018 Healthcare Conference in...

More
 

print email rss
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide